Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M701 Combined With Systemic Therapy in Malignant Ascites
NCT06266091Phase 2Completed
- Sponsor
- Wuhan YZY Biopharma Co., Ltd.
- Start
- Nov 2021
- Primary completion
- Feb 2024
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of M701 in malignant ascites, sponsored by Wuhan YZY Biopharma Co., Ltd.. Started Nov 2021; status: completed.
02
Drugs
M701
03
Conditions
malignant ascites
Beyond the preview
Go deeper on NCT06266091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06266091.